Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials

Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials

Background: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are approved for the treatment of disease activity and are effective in reducing relapses and new magnetic resonance imaging (MRI) lesions. However, disease activity generally subsides with time, and age-dependent changes in...

Full description

Bibliographic Details
Main Authors:	Yinan Zhang, Natalia Gonzalez Caldito, Afsaneh Shirani, Amber Salter, Gary Cutter, William Culpepper, Mitchell Wallin, Peter Kosa, Bibiana Bielekova, Fred Lublin, Olaf Stuve
Format:	Article
Language:	English
Published:	SAGE Publishing 2020-10-01
Series:	Therapeutic Advances in Neurological Disorders
Online Access:	https://doi.org/10.1177/1756286420969016

Similar Items

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
by: Yinan Zhang, et al.
Published: (2021-03-01)

Clinical trials in multiple sclerosis: milestones
by: Yinan Zhang, et al.
Published: (2018-07-01)

Evolution of clinical trials in multiple sclerosis
by: Yinan Zhang, et al.
Published: (2019-02-01)

Clinical trials in multiple sclerosis: potential future trial designs
by: Navid Manouchehri, et al.
Published: (2019-05-01)

Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis
by: Joshua L. Milstein, et al.
Published: (2019-11-01)

Extensive Healthy Donor Age/Gender Adjustments and Propensity Score Matching Reveal Physiology of Multiple Sclerosis Through Immunophenotyping
by: Paavali A. Hannikainen, et al.
Published: (2020-11-01)

Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis
by: Linh Pham, et al.
Published: (2021-02-01)

Biomarkers in Multiple Sclerosis
by: Roland Martin, et al.
Published: (2006-01-01)

Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?
by: Austin Negron, et al.
Published: (2020-12-01)

Isoniazid in autoimmunity: a trigger for multiple sclerosis?
by: Bardia Nourbakhsh, et al.
Published: (2014-09-01)

Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms
by: Amer Awad, et al.
Published: (2009-11-01)

Natalizumab: increased vigilance is required in treating patients with multiple sclerosis
by: Michael K. Racke, et al.
Published: (2008-11-01)

Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought
by: Marrie, Ruth Ann, et al.
Published: (2013-04-01)

Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study
by: Marrie, Ruth Ann, et al.
Published: (2014-02-01)

Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
by: Navid Manouchehri, et al.
Published: (2021-02-01)

The effect of smoking on the symptoms and progression of multiple sclerosis: a review
by: Afsaneh Shirani, et al.
Published: (2010-09-01)

Smartphone Level Test Measures Disability in Several Neurological Domains for Patients With Multiple Sclerosis
by: Alexandra K. Boukhvalova, et al.
Published: (2019-05-01)

Quantifications of CSF Apoptotic Bodies Do Not Provide Clinical Value in Multiple Sclerosis
by: Ruturaj Masvekar, et al.
Published: (2019-11-01)

Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity
by: Ruturaj Masvekar, et al.
Published: (2021-03-01)

A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
by: Amber Salter, et al.
Published: (2021-06-01)

Multiple sclerosis and chronic cerebrospinal venous insufficiency: a critical review
by: Amer M. Awad, et al.
Published: (2011-07-01)

From injection therapies to natalizumab: views on the treatment of multiple sclerosis
by: Roberto Bomprezzi, et al.
Published: (2012-03-01)

Development of a sensitive outcome for economical drug screening for progressive multiple sclerosis treatment
by: Peter Kosa, et al.
Published: (2016-08-01)

New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability
by: Ann Marie Weideman, et al.
Published: (2017-11-01)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
by: Dubey D, et al.
Published: (2015-09-01)

Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era
by: Ilya Kister, et al.
Published: (2018-09-01)

A complex role of herpes viruses in the disease process of multiple sclerosis.
by: Simone C Wuest, et al.
Published: (2014-01-01)

Body Mass Index in Multiple Sclerosis modulates ceramide-induced DNA methylation and disease courseResearch In Context
by: Kamilah Castro, et al.
Published: (2019-05-01)

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing—remitting multiple sclerosis (TIME MS)
by: Gina M. Remington, et al.
Published: (2010-01-01)

How implementation of systems biology into clinical trials accelerates understanding of diseases
by: Bibiana eBielekova, et al.
Published: (2014-06-01)

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis
by: Elliot M. Frohman, et al.
Published: (2010-01-01)

Patient perspectives on switching disease-modifying therapies in the NARCOMS registry
by: Salter AR, et al.
Published: (2014-07-01)

Symptomatic therapy in multiple sclerosis
by: Teresa C. Frohman, et al.
Published: (2011-03-01)

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis.
by: Pierre Branger, et al.
Published: (2016-01-01)

The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses
by: Suzi B. Claflin, et al.
Published: (2019-01-01)

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
by: Olaf Stuve, et al.
Published: (2019-06-01)

Cerebellar volume as imaging outcome in progressive multiple sclerosis.
by: Matilde Inglese, et al.
Published: (2017-01-01)

Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.
by: Karen Yao, et al.
Published: (2008-01-01)

Modifiable environmental factors in multiple sclerosis
by: Yara Dadalti Fragoso
Published: (2014-11-01)

Disease-modifying agents in multiple sclerosis
by: Coyle P
Published: (2009-01-01)

Cannot write session to /tmp/vufind_sessions/sess_ovjlu4oaubuec4tdmaffq9uthg